Loading
SI
Surmodics Inc Stock: price and insider trades · United States
Surmodics Inc: what insiders have been doing
Every trade that managers of Surmodics Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Surmodics Inc logged 11 filings by 11 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
With 11 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2016, counts no purchases against 10 sales.
There has been no open-market purchase by an insider of Surmodics Inc for at least a year.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
138
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€2M
10 ops. · all time
Who traded when
BuySaleTimothy J. Arens1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended September 2024 · cache
Income statement
RevenueUS$108.6M
Net income-US$9.9M-9.2% margin
Last declaration on 19 November 2025
Declarations138 total
51,478 sharesCommon StockSEC:0001193125-25-288455:0
8,155 sharesCommon StockSEC:0001193125-25-288452:0
21,040 sharesCommon StockSEC:0001193125-25-288450:0
34,703 sharesCommon StockSEC:0001193125-25-288446:0
40,183 sharesCommon StockSEC:0001193125-25-288443:0
13,978 sharesCommon StockSEC:0001193125-25-288441:0
37,240 sharesCommon StockSEC:0001193125-25-288439:0
30,008 sharesCommon StockSEC:0001193125-25-288436:0
67,299 sharesCommon StockSEC:0001193125-25-288432:0
61,631 sharesCommon StockSEC:0001193125-25-288427:0
192,056 sharesCommon StockSEC:0001193125-25-288424:0
2,640 shares@ US$27.30100.0% of flowCommon StockSEC:0000950170-25-024156:0
5,275 shares@ US$27.3044.6% of flowCommon StockSEC:0000950170-25-022487:0
5,275 shares@ US$27.3044.4% of flowCommon StockSEC:0000950170-25-022479:0
7,358 shares@ US$27.3068.8% of flowCommon StockSEC:0000950170-25-009976:0
4,248 shares@ US$39.916.5% of flowCommon StockSEC:0000950170-24-134181:0
152 shares@ US$39.9121.5% of flowCommon StockSEC:0000950170-24-134171:0
668 shares@ US$39.9127.5% of flowCommon StockSEC:0000950170-24-134175:0
1,034 shares@ US$39.912.5% of flowCommon StockSEC:0000950170-24-134169:0
1,265 shares@ US$39.913.0% of flowCommon StockSEC:0000950170-24-134183:0
946 shares@ US$39.9128.5% of flowCommon StockSEC:0000950170-24-134173:0
959 shares@ US$39.913.7% of flowCommon StockSEC:0000950170-24-134168:0
1,312 shares@ US$39.4538.9% of flowCommon StockSEC:0000950170-24-132951:0
1,534 shares@ US$39.455.8% of flowCommon StockSEC:0000950170-24-132965:0
387 shares@ US$39.4554.0% of flowCommon StockSEC:0000950170-24-132955:0
25 of 138 declarations
About Surmodics Inc
Surmodics Inc. is a U.S.-based medical technology company listed on the NASDAQ market in the United States, focused on advanced surface technologies, interventional medical devices, and in vitro diagnostics components. Founded in 1979 and headquartered in Eden Prairie, Minnesota, the company built its franchise on deep expertise in surface science, with a recognized position in hydrophilic, hemocompatible, and drug-delivery coatings for intravascular medical devices. Over time, Surmodics has evolved from a specialized coatings business into a broader development and manufacturing partner, combining design, formulation, testing, scale-up, and production capabilities for complex medical products.
The company is organized around several complementary business lines. Performance Coatings remains the historical core: these technologies are designed to improve lubricity, trackability, and overall procedural performance of devices used in coronary, peripheral, neurovascular, and structural heart applications. Its In Vitro Diagnostics business supplies chemical components, surfaces, and related materials used in immunoassays and microarrays, providing diversification beyond interventional medtech. Surmodics also offers Contract Development & Manufacturing services, including catheter and complex-device manufacturing capabilities, with operations in the U.S. and Ireland. In addition, its Interventional Products portfolio includes therapies for peripheral arterial and venous disease, such as the Pounce and Sublime platforms, alongside drug-coated balloon technology under the SurVeil brand.
Read moreShow less
From a competitive standpoint, Surmodics is a focused niche player rather than a large diversified medtech conglomerate. Its edge comes from technical depth, intellectual property, coating performance, and its ability to support customers from concept through commercialization. In a highly regulated industry, the company benefits from long-standing relationships with major medical device manufacturers, innovative startups, and strategic global partners. Geographically, the business remains centered in the United States, with Eden Prairie as the main hub and a meaningful industrial footprint in Ireland.
Recent company highlights have centered on product pipeline expansion and commercialization milestones. Surmodics has highlighted broader clinical use of its Preside coating platform, new releases within the Pounce thrombectomy family, and continued progress in its drug-coated balloon franchise. For investors, the core question is whether Surmodics can convert its technology platform into sustained commercial growth while managing the regulatory, reimbursement, and competitive pressures inherent to medtech innovation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
